Healthcare Industry News: US Diagnostics
News Release - March 3, 2008
Celerus Diagnostics Launches Rapid Diagnostic Tool
Wave(TM) System Causes Splash in IndustryDENVER--(HSMN NewsFeed)--CelerUS Diagnostics, the rapid cancer diagnostics company, today announced the launch of its revolutionary new system, the WaveTM, at the United States and Canada Academy of Pathology (USCAP) meeting. Capable of producing immunohistochemistry (IHC) results in as little as 15 minutes, the WaveTM System will accelerate lab throughput, enable intra-operative testing, and provide real-time pathology to requesting physicians.
“This system not only increases the efficiency of the lab,” said Michael Sarrasin, CEO, “but improves the patient experience by dramatically reducing the time they need to wait for results. We are extremely proud to present such a rapid results oriented system.”
By repeatedly opening and closing slide segments, the patented Dynamic Replenishment TechnologyTM creates kinetic “waves” which vigorously mix and refresh reagents. Unlike the time-consuming, passive, gravity-based methods of the past, this active recharging process continuously floods antigenic sites on the tissue with new waves of primary and secondary reagents, providing faster and more efficient biding, accelerating reaction times, and enabling unprecedented 15-minute IHC turnaround times.
“Providing results in less than 15 minutes is a technical breakthrough that has resounding effects in the lab, with the physician, and most importantly with the patient,” said Dr. Marc Key, Chief Scientific Officer. “After years of development, we are excited to present it to the industry.”
About Celerus:
Founded in 2004 in Santa Barbara, California, CelerUS Diagnostics is committed to enhancing the diagnostic capabilities of the pathology laboratory. Celerus technology provides the capability to decentralize testing, and move results closer to the patient for real time decision making. For more information, please visit our website: www.celerusdiagnostics.com or contact us at 805.685.0797.
This release contains forward-looking statements that involve risks and uncertainties, including, but not limited to, CelerUS Diagnostics’ ability to successfully complete its development program, competitive pressures and other factors such as the introduction or regulatory approval of new products by our competitors and pricing of competing products and the resulting effects on sales and pricing of our products, disruptions or other problems with our sources of supply, significant product liability or other claims, difficulties with new product development and market acceptance, changes in the mix of our products sold, patent conflicts, product recalls, United States Food and Drug Administration (FDA) delay in or approval or rejection of new or existing products, changes in Medicare, Medicaid or third-party reimbursement policies, changes in government regulation, use of hazardous or environmentally sensitive materials, our inability to implement new information technology systems, our inability to integrate new acquisitions, and other events. This press release reflects information as of the date of this press release, and the company takes no responsibility in updating the information contained herein now or in the future.
Source: Celerus Diagnostics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!